Transcriptomic signature predicts the distant relapse in patients with ER+ breast cancer treated with tamoxifen for five years

Zhou,Hao; Lv,Qingfu; Guo,Zhaoji

doi:10.3892/mmr.2017.8234

Transcriptomic signature predicts the distant relapse in patients with ER+ breast cancer treated with tamoxifen for five years

Authors:
- Hao Zhou
- Qingfu Lv
- Zhaoji Guo
View Affiliations

Affiliations: Department of General Surgery, The First Affiliated Hospital of SooChow University, Suzhou, Jiangsu 215006, P.R. China
Published online on: December 8, 2017 https://doi.org/10.3892/mmr.2017.8234
Pages: 3152-3157

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tamoxifen is the most commonly used drug to treat estrogen receptor positive (ER+) breast cancer. However, many patients with ER+ breast cancer have experienced resistance and other adverse side effects following treatment with tamoxifen. Furthermore, clinical and pathological parameters have thus far failed to predict the efficiency of tamoxifen administration. Therefore, gene signature based models for the prediction of survival time of such patients are urgently needed. In the current study, gene expression levels and follow‑up information of samples from GSE17705 and GSE22219 databases were used to construct a risk score model based on Cox multivariate regression. The expression levels of 10 genes were included in the model: CCNB2, CCNA2, FOXD1, WSB2, RBPMS, CTDSP1, BIN3, SLBP, EPRS, FTO. The samples in the high‑risk group had a relative early distant relapse time period (median survival time of 3.75 years) compared with the patients in the low risk group (median survival time of 6.5 years, P<0.01). For further validation, a further two independent datasets (GSE26971, GSE58644) were assessed. The overall survival time period of patients with high‑risk scores in these datasets was significantly longer than those with low‑risk scores (P<0.01). Furthermore, the associations between clinical parameters and risk score were investigated, and it was revealed that the risk score was significantly correlated with tumor age, tumor stage and grade. In addition, a 5‑year survival nomogram was plotted in order to facilitate the utilization of risk score along with other clinical data. In summary, using the transcriptomic profile, a multi‑gene expression based risk score was developed and was revealed as being able to successfully predict the outcome of patients with ER+ breast cancer treated with tamoxifen for 5 years.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2012. View Article : Google Scholar
2	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
3	Zembutsu H: Pharmacogenomics toward personalized tamoxifen therapy for breast cancer. Pharmacogenomics. 16:287–296. 2015. View Article : Google Scholar : PubMed/NCBI
4	Liu J, Prager-van der Smissen WJ, Look MP, Sieuwerts AM, Smid M, Meijer-van Gelder ME, Foekens JA, Hollestelle A and Martens JW: GATA3 mRNA expression, but not mutation, associates with longer progression-free survival in ER-positive breast cancer patients treated with first-line tamoxifen for recurrent disease. Cancer Lett. 376:104–109. 2016. View Article : Google Scholar : PubMed/NCBI
5	Gu Y, Chen T, Li G, Xu C, Xu Z, Zhang J, He K, Zheng L, Guan Z, Su X, et al: Lower Beclin 1 downregulates HER2 expression to enhance tamoxifen sensitivity and predicts a favorable outcome for ER positive breast cancer. Oncotarget. 8:52156–52177. 2016.PubMed/NCBI
6	Reijm EA, Timmermans AM, Look MP, Meijer-van Gelder ME, Stobbe CK, van Deurzen CH, Martens JW, Sleijfer S, Foekens JA, Berns PM and Jansen MP: High protein expression of EZH2 is related to unfavorable outcome to tamoxifen in metastatic breast cancer. Ann Oncol. 25:2185–2190. 2014. View Article : Google Scholar : PubMed/NCBI
7	Bou Samra E, Klein B, Commes T and Moreaux J: Development of gene expression-based risk score in cytogenetically normal acute myeloid leukemia patients. Oncotarget. 3:1–832. 2012. View Article : Google Scholar : PubMed/NCBI
8	Salazar R, Roepman P, Capella G, Moreno V, Simon I, Dreezen C, Lopez-Doriga A, Santos C, Marijnen C, Westerga J, et al: Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol. 29:17–24. 2011. View Article : Google Scholar : PubMed/NCBI
9	Bou Samra E, Klein B, Commes T and Moreaux J: Identification of a 20-gene expression-based risk score as a predictor of clinical outcome in chronic lymphocytic leukemia patients. Biomed Res Int. 2014:4231742014. View Article : Google Scholar : PubMed/NCBI
10	Kim SK, Kim SY, Kim JH, Roh SA, Cho DH, Kim YS and Kim JC: A nineteen gene-based risk score classifier predicts prognosis of colorectal cancer patients. Mol Oncol. 8:1653–1666. 2014. View Article : Google Scholar : PubMed/NCBI
11	Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC and Müller M: pROC: An open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics. 12:772011. View Article : Google Scholar : PubMed/NCBI
12	Gao YF, Zhu T, Mao XY, Mao CX, Li L, Yin JY, Zhou HH and Liu ZQ: Silencing of Forkhead box D1 inhibits proliferation and migration in glioma cells. Oncol Rep. 37:1196–1202. 2017. View Article : Google Scholar : PubMed/NCBI
13	Gao T, Han Y, Yu L, Ao S, Li Z and Ji J: CCNA2 is a prognostic biomarker for ER+ breast cancer and tamoxifen resistance. PLoS One. 9:e917712014. View Article : Google Scholar : PubMed/NCBI
14	Shubbar E, Kovács A, Hajizadeh S, Parris TZ, Nemes S, Gunnarsdóttir K, Einbeigi Z, Karlsson P and Helou K: Elevated cyclin B2 expression in invasive breast carcinoma is associated with unfavorable clinical outcome. BMC Cancer. 13:12013. View Article : Google Scholar : PubMed/NCBI
15	Tan A, Dang Y, Chen G and Mo Z: Overexpression of the fat mass and obesity associated gene (FTO) in breast cancer and its clinical implications. Int J Clin Exp Pathol. 8:13405–13410. 2015.PubMed/NCBI
16	Zeng X, Ban Z, Cao J, Zhang W, Chu T, Lei D and Du Y: Association of FTO mutations with risk and survival of breast cancer in a Chinese population. Dis Markers. 2015:1010322015. View Article : Google Scholar : PubMed/NCBI
17	Sun T, Fu J, Shen T, Lin X, Liao L, Feng XH and Xu J: The small c-terminal domain phosphatase 1 inhibits cancer cell migration and invasion by dephosphorylating ser(p)68-twist1 to accelerate twist1 protein degradation. J Biol Chem. 291:11518–11528. 2016. View Article : Google Scholar : PubMed/NCBI
18	Katsyv I, Wang M, Song WM, Zhou X, Zhao Y, Park S, Zhu J, Zhang B and Irie HY: EPRS is a critical regulator of cell proliferation and estrogen signaling in ER+ breast cancer. Oncotarget. 7:69592–69605. 2016.PubMed/NCBI
19	Fu J, Cheng L, Wang Y, Yuan P, Xu X, Ding L, Zhang H, Jiang K, Song H, Chen Z and Ye Q: The RNA-binding protein RBPMS1 represses AP-1 signaling and regulates breast cancer cell proliferation and migration. Biochim Biophys Acta. 1853:1–13. 2015. View Article : Google Scholar : PubMed/NCBI